PLoS ONE (Jan 2013)

SHBG is an important factor in stemness induction of cells by DHT in vitro and associated with poor clinical features of prostate carcinomas.

  • Yuanyuan Ma,
  • Dongming Liang,
  • Jian Liu,
  • Jian-Guo Wen,
  • Einar Servoll,
  • Gudmund Waaler,
  • Thorstein Sæter,
  • Karol Axcrona,
  • Ljiljana Vlatkovic,
  • Ulrika Axcrona,
  • Elisabeth Paus,
  • Yue Yang,
  • Zhiqian Zhang,
  • Gunnar Kvalheim,
  • Jahn M Nesland,
  • Zhenhe Suo

DOI
https://doi.org/10.1371/journal.pone.0070558
Journal volume & issue
Vol. 8, no. 7
p. e70558

Abstract

Read online

Androgen plays a vital role in prostate cancer development. However, it is not clear whether androgens influence stem-like properties of prostate cancer, a feature important for prostate cancer progression. In this study, we show that upon DHT treatment in vitro, prostate cancer cell lines LNCaP and PC-3 were revealed with higher clonogenic potential and higher expression levels of stemness related factors CD44, CD90, Oct3/4 and Nanog. Moreover, sex hormone binding globulin (SHBG) was also simultaneously upregulated in these cells. When the SHBG gene was blocked by SHBG siRNA knock-down, the induction of Oct3/4, Nanog, CD44 and CD90 by DHT was also correspondingly blocked in these cells. Immunohistochemical evaluation of clinical samples disclosed weakly positive, and areas negative for SHBG expression in the benign prostate tissues, while most of the prostate carcinomas were strongly positive for SHBG. In addition, higher levels of SHBG expression were significantly associated with higher Gleason score, more seminal vesicle invasions and lymph node metastases. Collectively, our results show a role of SHBG in upregulating stemness of prostate cancer cells upon DHT exposure in vitro, and SHBG expression in prostate cancer samples is significantly associated with poor clinicopathological features, indicating a role of SHBG in prostate cancer progression.